Enhanced Combination Therapies for Progeroid Diseases and Conditions

The present inventive concept discloses improved combination therapies for treating progeroid diseases and conditions, cellular aging, and cardiovascular and bone diseases, building upon the original patent's foundation by introducing personalized treatment approaches, optimized dosing regimens, and advanced patient monitoring systems.

The original patent, 'Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis,' provided a foundation for treating progeroid diseases and conditions using combination therapies comprising farnesyltransferase inhibitors and mTOR inhibitors. However, the original patent had limitations in terms of dosing regimens, patient monitoring, and treatment personalization. The present inventive concept addresses these limitations by introducing advanced systems, methods, and compositions that enhance treatment efficacy, safety, and efficiency.

The present inventive concept encompasses a range of innovative solutions, including a system for treating progeroid diseases and conditions that combines a combination therapy module with a patient monitoring module, allowing for real-time tracking of treatment efficacy and adjusting dosages accordingly. Additionally, a method for optimizing treatment of cellular aging-related conditions involves identifying a subject's genetic profile related to lamin A protein expression and administering a personalized combination therapy based on this profile. Furthermore, a composition for treating cardiovascular and bone diseases features a synergistic blend of a farnesyltransferase inhibitor and an mTOR inhibitor, while a kit for treating progeroid diseases and conditions provides a farnesyltransferase inhibitor, an mTOR inhibitor, and instructions for administering the combination therapy. Finally, a system for predicting treatment outcomes for progeroid diseases and conditions leverages a database of treatment efficacy data and a predictive analytics module to determine the likelihood of successful treatment based on a subject's genetic profile and medical history.

The present inventive concept's novelty lies in its introduction of personalized treatment approaches, optimized dosing regimens, and advanced patient monitoring systems, which are not disclosed in the original patent. The inventive step resides in the combination of these features, which provide a synergistic effect in enhancing treatment efficacy, safety, and efficiency.

Alternative embodiments of the inventive concept could include variations in the combination therapy module, such as using different types of farnesyltransferase inhibitors or mTOR inhibitors, or incorporating additional therapeutic agents. The patient monitoring module could be adapted for use with different types of medical devices or data analytics platforms. The predictive analytics module could be modified to incorporate additional data sources or machine learning algorithms.

The present inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of progeroid diseases and conditions, cellular aging, and cardiovascular and bone diseases. The market for combination therapies is expected to grow significantly in the coming years, driven by the increasing need for effective treatments for these conditions. The inventive concept's focus on personalized treatment approaches and advanced patient monitoring systems positions it for strong market adoption and potential partnerships with leading pharmaceutical companies.